SCHEMBL2656129

SCHEMBL2656129

CCNCc1ccc(C(=O)Cc2nnn(C(C)(C)OC)n2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.37
HDAC1 Q13547 2/20 0.36
HDAC6 Q9UBN7 2/20 0.36
BCHE P06276 1/20 0.35
ACHE P22303 1/20 0.35
LMNA P02545 3/20 0.34
L3MBTL1 Q9Y468 2/20 0.33
NPC1 O15118 2/20 0.33
KMT2A Q03164 2/20 0.33
MAPK1 P28482 2/20 0.33
MEN1 O00255 1/20 0.33
EPHX2 P34913 1/20 0.33
RAB9A P51151 1/20 0.33
NR1H4 Q96RI1 1/20 0.33
TSHR P16473 1/20 0.33
HDAC3 O15379 1/20 0.33
HDAC4 P56524 1/20 0.33
HDAC7 Q8WUI4 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC10 Q969S8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2643657 0.82 PTGDR2 (0.37) HPGDHDAC1BCHEACHELMNA
SCHEMBL2665699 0.69 HTT (0.49) LMNAL3MBTL1EPHX2NR1H4S1PR2
SCHEMBL2655924 0.65 HPGD (0.62) HPGDLMNANPC1KMT2AMEN1
Hydrochloric Acid SCHEMBL28375861 0.64 HPGD (0.60) HPGDLMNANPC1KMT2AMEN1
SCHEMBL25007242 0.64 HSD17B3 (0.56) HPGDL3MBTL1KMT2ARAB9ASMN1; SMN2
SCHEMBL2659138 0.64 SMN1; SMN2 (0.35) HPGDHDAC1HDAC6LMNAL3MBTL1
SCHEMBL3671659 0.63 SMN1; SMN2 (0.43) HDAC6L3MBTL1KMT2AMEN1EPHX2
SCHEMBL2656861 0.63 MLYCD (0.47) HPGDHDAC1HDAC6LMNAL3MBTL1
SCHEMBL2663103 0.62 ALDH1A1 (0.65) HPGDHDAC6L3MBTL1KMT2AEPHX2
SCHEMBL18602133 0.62 KMT2A (0.57) HPGDHDAC1HDAC6LMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030203946-A1 Glucagon antagonists/inverse agonists NOVO NORDISK A/S (DK) 2003-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030203946-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR HPGD 1687/4885HDAC1 2196/4885HDAC6 3661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.